Cannabidiol - GW Pharmaceuticals

Drug Profile

Cannabidiol - GW Pharmaceuticals

Alternative Names: CBD - GW Pharmaceuticals; Epidiolex; GW-42003; GWP-42003; GWP-42003-P

Latest Information Update: 16 Dec 2016

Price : $50

At a glance

  • Originator GW Pharmaceuticals
  • Developer GW Pharmaceuticals; University of Alabama at Birmingham; University of Utah
  • Class Analgesics; Antiepileptic drugs; Antipsychotics; Anxiolytics; Cannabinoids; Muscle relaxants; Neuroprotectants; Small molecules
  • Mechanism of Action Antioxidants; Cannabinoid receptor CB1 antagonists; Cannabinoid receptor CB2 antagonists; Cannabinoid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lennox-Gastaut syndrome; Dravet syndrome; Cerebral ischaemia; Infantile spasms; Tuberous sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Dravet syndrome; Infantile spasms; Lennox-Gastaut syndrome; Tuberous sclerosis
  • Phase II Epilepsy; Opioid abuse; Parkinson's disease; Schizophrenia
  • Phase I Cerebral ischaemia
  • Preclinical Duchenne muscular dystrophy; Ovarian cancer
  • Discontinued Dyslipidaemias; Non-alcoholic fatty liver disease; Type 2 diabetes mellitus; Ulcerative colitis

Most Recent Events

  • 05 Dec 2016 Phase-I clinical trials in Cerebral ischaemia (In neonates) in USA (IV)
  • 05 Dec 2016 Phase-III clinical trials in Infantile spasms (Treatment-resistant) in USA (PO) , (NCT02953548)
  • 05 Dec 2016 GW Pharmaceuticals announces intention to submit MAA to EMA in the second half of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top